Journal
BMC VETERINARY RESEARCH
Volume 11, Issue -, Pages -Publisher
BMC
DOI: 10.1186/s12917-015-0514-6
Keywords
Atopic dermatitis; Canine; Dogs; Evidence-based medicine; Guidelines; Treatment
Categories
Funding
- Aratana Therapeutics (Kansas City, Kansas, USA)
- Boehringer Ingelheim Vetmedica (St Joseph, Missouri, USA)
- Ceva (Libourne, France)
- Elanco Animal Health (Greenfield, Indiana, USA)
- Gour Medical (Zur, Switzerland)
- NexVet (Melbourne
- Australia)
- Novartis Animal Health (Basel, Switzerland)
- Royal Canin (Aimargues, France)
- Vetoquinol (Paris, France)
- Virbac (Carros, France)
- Zoetis (Florham Park, New Jersey, USA)
- Delmont Laboratories (Swarthmore, Pennsylvania, USA)
- Heska (Fort Collins, Colorado USA)
- Greer Laboratories (Lenoir, North Carolina, USA)
- Bayer Animal Health (Leverkusen, Germany)
- Dechra Pharmaceuticals (Lostrop, United Kingdom)
- Elanco (Bad Homburg, Germany)
- Laboratoire de Dermo-Cosmetique Animale (Castres, France)
- Selectavet (Weyam, Germany)
- Zoetis (Berlin, Germany)
- Zoetis (Walton Oaks, UK)
- lams (Proctor & Gamble Pet Care, London, UK)
- Idexx Laboratories (Wetherby, UK)
- Avacta Animal Health (Wetherby, UK)
- Vetoquinol (Buckingham, UK)
- Ceva (Amersham, UK)
- Dechra Veterinary Products (Shrewsbury, UK)
- Elanco Animal Health (Neuilly, France)
- Novartis Animal Health France (Rueil Malmaison, France)
- Zoetis (Paris, France)
- Merck-Merial (Lyon, France)
- Biovac (Angers, France)
Ask authors/readers for more resources
Background: In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document. Results: The treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD. Conclusions: This first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available